Selective Protection of Normal Cells during Chemotherapy by RY4 Peptides

Abstract

Mitochondrial targeted Szeto-Schiller (SS) peptides have recently gained attention for their antioxidative stress ability; however, the functional variations between normal and cancer cells have not been determined. Here, we report the results of such experiments conducted with a newly designed class of peptide called RY4, which is based on SS peptide sequence characteristics. The RY4 peptide exhibits distinct differences in antioxidative stress response between normal and cancer cells when challenged with chemotherapeutics like the glycolytic inhibitor dichloroacetate (DCA), the platinating agent carboplatin, and the DNA damage inducer doxorubicin. Interestingly, only normal human cells were protected by the RY4 peptide and catalase (CAT) activity was significantly enhanced in normal but not tumor cells when incubated with RY4. Pull-down, coimmunoprecipitation, and LC/MS-MS proteomic analysis demonstrated that RY4 and catalase are capable of forming protein complexes. Finally, in vivo efficacy was evaluated by intraperitoneal administration of RY4 into a lung cancer xenograft model, which revealed significant myocardiocyte protection from doxorubicin-induced cardiotoxicity without diminishing doxorubicin's tumoricidal effects. Taken together, RY4 offers selective protection to normal cells from chemotherapy-induced toxicity by enhancing the activity of cellular antioxidant enzymes.

Identifying the most effective hydatid cyst fluid fraction for anticancer vaccination of 4T1 breast tumor-bearing mice

“…Immunotherapy is an alternative method for cancer treatment. [36] It has many branches such as T-cell therapy, dendritic cells therapy, and vaccination, which is one of the most popular and interesting techniques of immune therapy. Immunization is a safe, low-cost, and effective therapeutic method.…”

Selective Cytotoxicity of 1,3,4-Thiadiazolium Mesoionic Derivatives on Hepatocarcinoma Cells (HepG2)

“…The high toxicity of drugs toward non-tumoral cells and the resistance to treatment constitute great problems in present chemotherapy [ 8 , 9 ]. Drug toxicity usually limits the concentration usable for the treatments, as well as the frequency of administrations, further affecting curing efficiency [ 10 ]. Additionally, tumor cells may become resistant to drugs through different mechanisms.…”